Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
ALIM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.37%333.610.0%$4529.69m
NVAXNovavax, Inc. -3.43%160.5579.4%$722.22m
BNTXBioNTech SE 0.67%262.850.0%$709.55m
AMGNAmgen, Inc. 1.80%206.781.4%$547.92m
SNSSSunesis Pharmaceuticals, Inc. -1.92%6.140.7%$429.21m
REGNRegeneron Pharmaceuticals, Inc. 1.59%552.112.7%$426.22m
GILDGilead Sciences, Inc. 1.52%66.901.0%$414.02m
CCXIChemoCentryx, Inc. 3.76%33.652.9%$399.69m
ILMNIllumina, Inc. 0.87%414.083.3%$377.90m
XLRNAcceleron Pharma, Inc. 0.43%173.745.3%$364.00m
VRTXVertex Pharmaceuticals, Inc. 2.55%185.411.9%$264.85m
BIIBBiogen, Inc. -0.59%268.131.7%$232.27m
OCGNOcugen, Inc. 0.85%8.330.0%$180.05m
XENEXenon Pharmaceuticals, Inc. -2.96%29.810.4%$166.66m
DNAGinkgo Bioworks Holdings, Inc. 20.21%14.810.0%$162.54m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.